NHLH2

Across TCGA pan-cancer cohorts, NHLH2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NHLH2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NHLH2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NHLH2 expression acts as an unfavorable survival marker.

LIHC, PRAD, and ESCA are the cancer types where NHLH2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.062	0.544	<.001	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NHLH2–LIHC (DFS)

Open the LIHC breakdown →